サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1489161

リシノプリルの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Lisinopril Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 221 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.70円
リシノプリルの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年05月01日
発行: Value Market Research
ページ情報: 英文 221 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

リシノプリル市場の世界需要は、2023年の20億9,000万米ドルから2032年にはほぼ33億5,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは5.36%です。

リシノプリルはアンジオテンシン変換酵素（ACE）阻害薬に分類され、主に高血圧（高血圧症）と心不全の治療に処方されます。そのメカニズムとしては、血管を弛緩させることで血圧を下げ、血流を改善します。また、心臓発作後の生存率の改善や、糖尿病に関連する特定の腎臓疾患の治療にも処方されます。通常、1日1回、食事の有無にかかわらず経口投与されます。一般的な副作用は、めまい、頭痛、咳などです。血圧を効果的に管理することで、脳卒中、心臓発作、腎障害のリスクを低下させます。

市場力学

リシノプリルはこれらの症状を管理するために広く処方されているため、高血圧と心血管疾患の発生が増加していることが重要な促進要因となっています。世界人口の増加と生活習慣に関連した健康問題の増加に伴い、効果的な降圧薬に対する需要は増加の一途をたどっています。さらに、有効性と安全性が実証されていることから、医療プロバイダーの間で好んで使用されています。発展途上地域における医療アクセスの拡大も重要な要因です。より多くの人々が医療を受けられるようになるにつれ、高血圧の診断と治療が普及し、市場の成長を後押ししています。さらに、高齢者は高血圧や関連する心血管疾患にかかりやすいため、高齢化も市場成長に大きく寄与しています。また、製薬会社はリシノプリルの利点を患者や医療従事者に伝えるため、マーケティングや啓発キャンペーンに投資しており、これがリシノプリルの採用を後押ししています。最後に、医薬品製造の進歩により、高品質のリシノプリルをより手頃な価格で製造できるようになり、より幅広い患者層がリシノプリルにアクセスできるようになりました。しかし、ジェネリック医薬品の出現と潜在的な副作用が、今後数年間の市場成長の課題となる可能性があります。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールはリシノプリルの世界市場における各セグメントを包括的に評価することもできます。リシノプリル業界の成長と動向は、この調査への全体的なアプローチを提供します。

市場セグメンテーション

リシノプリル市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家がそれぞれの製品またはサービスのターゲット層を特定する上で、今後の機会を支援します。

用量別

  • 錠剤
  • 液剤

用量強度別

  • 10 Mg
  • 20 Mg
  • 25 Mg

患者年齢層別

  • 小児
  • 成人

用途別

  • 高血圧症
  • 心不全
  • 心臓発作
  • 糖尿病性腎臓病
  • その他

流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおけるリシノプリル市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 リシノプリル：産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 リシノプリルの世界市場分析：用量別

  • 概要：用量別
  • 実績・予測データ分析：用量別
  • 錠剤
  • 液剤

第6章 リシノプリルの世界市場分析：用量強度別

  • 概要：用量強度別
  • 実績・予測データ分析：用量強度別
  • 10 Mg
  • 20 Mg
  • 25 Mg

第7章 リシノプリルの世界市場分析：患者年齢層別

  • 概要：患者年齢層別
  • 実績・予測データ分析：患者年齢層別
  • 小児
  • 成人

第8章 リシノプリルの世界市場分析：用途別

  • 概要：用途別
  • 実績・予測データ分析：用途別
  • 高血圧症
  • 心不全
  • 心臓発作
  • 糖尿病性腎臓病
  • その他

第9章 リシノプリルの世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績・予測データ分析：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 リシノプリルの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第11章 リシノプリル企業の競合情勢

  • リシノプリル市場競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品発売
  • その他の開発

第12章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AbbVie Inc.
  • Amneal Pharmaceutical Inc.
  • AstraZeneca
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Hikma Pharmaceutical PLC.
  • Lupin Limited
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Vitaris Inc.
  • Zydus Lifesciences Limited
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Dosage (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Liquid Market Sales By Geography (USD MN)
  • Analysis By Dosage Strength (USD MN)
  • 10 Mg Market Sales By Geography (USD MN)
  • 20 Mg Market Sales By Geography (USD MN)
  • 25 Mg Market Sales By Geography (USD MN)
  • Analysis By Patient Age Group (USD MN)
  • Children Market Sales By Geography (USD MN)
  • Adults Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Hypertension Market Sales By Geography (USD MN)
  • Heart Failure Market Sales By Geography (USD MN)
  • Heart Attack Market Sales By Geography (USD MN)
  • Diabetic Kidney Disease Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Lisinopril Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Lisinopril Report
  • Market Research Process
  • Market Research Methodology
  • Global Lisinopril Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Dosage
  • Market Attractiveness Analysis By Dosage Strength
  • Market Attractiveness Analysis By Patient Age Group
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Dosage (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Liquid Market Sales By Geography (USD MN)
  • Global Market Analysis By Dosage Strength (USD MN)
  • 10 Mg Market Sales By Geography (USD MN)
  • 20 Mg Market Sales By Geography (USD MN)
  • 25 Mg Market Sales By Geography (USD MN)
  • Global Market Analysis By Patient Age Group (USD MN)
  • Children Market Sales By Geography (USD MN)
  • Adults Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Hypertension Market Sales By Geography (USD MN)
  • Heart Failure Market Sales By Geography (USD MN)
  • Heart Attack Market Sales By Geography (USD MN)
  • Diabetic Kidney Disease Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114732

The global demand for Lisinopril Market is presumed to reach the market size of nearly USD 3.35 Billion by 2032 from USD 2.09 Billion in 2023 with a CAGR of 5.36% under the study period 2024-2032.

Lisinopril is classified as an angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed to treat high blood pressure (hypertension) and heart failure. Its mechanism involves relaxing blood vessels, which reduces blood pressure and improves blood flow. It is also prescribed to improve survival rates after heart attacks and to treat certain kidney conditions related to diabetes. Typically, it is taken orally, once a day, with or without food. Common side effects include dizziness, headaches, and cough. By effectively managing blood pressure, it helps lower the risk of strokes, heart attacks, and kidney problems.

MARKET DYNAMICS

The growing occurrence of hypertension and cardiovascular diseases is a significant driver, as lisinopril is widely prescribed to manage these conditions. With a growing global population and an increase in lifestyle-related health issues, the demand for effective antihypertensive medications continues to rise. Additionally, the drug's proven efficacy and safety profile make it a favored option among healthcare providers. The ongoing expansion of healthcare access in developing regions is another important factor. As more people gain access to medical care, the diagnosis and treatment of hypertension become more widespread, boosting the market growth. Moreover, the aging population contributes significantly to market growth, as older adults are more susceptible to hypertension and related cardiovascular conditions. Pharmaceutical companies are also investing in marketing and awareness campaigns to educate patients and healthcare professionals about the benefits of lisinopril, which helps to drive its adoption. Lastly, advancements in pharmaceutical manufacturing have enabled high-quality lisinopril production at more affordable prices, making it accessible to a broader patient base. However, the emergence of generic alternatives and potential side effects may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Lisinopril. The growth and trends of Lisinopril industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Lisinopril market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage

  • Tablet
  • Liquid

By Dosage Strength

  • 10 Mg
  • 20 Mg
  • 25 Mg

By Patient Age Group

  • Children
  • Adults

By Application

  • Hypertension
  • Heart Failure
  • Heart Attack
  • Diabetic Kidney Disease
  • Other

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lisinopril market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lisinopril market include AbbVie Inc., Amneal Pharmaceutical Inc., AstraZeneca, Apotex Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Cipla Limited, Hikma Pharmaceutical PLC., Lupin Limited, Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Vitaris Inc., Zydus Lifesciences Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. LISINOPRIL - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Dosage
    • 3.7.2 Market Attractiveness Analysis By Dosage Strength
    • 3.7.3 Market Attractiveness Analysis By Patient Age Group
    • 3.7.4 Market Attractiveness Analysis By Application
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE

  • 5.1. Overview By Dosage
  • 5.2. Historical and Forecast Data Analysis By Dosage
  • 5.3. Tablet Historic and Forecast Sales By Regions
  • 5.4. Liquid Historic and Forecast Sales By Regions

6. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE STRENGTH

  • 6.1. Overview By Dosage Strength
  • 6.2. Historical and Forecast Data Analysis By Dosage Strength
  • 6.3. 10 Mg Historic and Forecast Sales By Regions
  • 6.4. 20 Mg Historic and Forecast Sales By Regions
  • 6.5. 25 Mg Historic and Forecast Sales By Regions

7. GLOBAL LISINOPRIL MARKET ANALYSIS BY PATIENT AGE GROUP

  • 7.1. Overview By Patient Age Group
  • 7.2. Historical and Forecast Data Analysis By Patient Age Group
  • 7.3. Children Historic and Forecast Sales By Regions
  • 7.4. Adults Historic and Forecast Sales By Regions

8. GLOBAL LISINOPRIL MARKET ANALYSIS BY APPLICATION

  • 8.1. Overview By Application
  • 8.2. Historical and Forecast Data Analysis By Application
  • 8.3. Hypertension Historic and Forecast Sales By Regions
  • 8.4. Heart Failure Historic and Forecast Sales By Regions
  • 8.5. Heart Attack Historic and Forecast Sales By Regions
  • 8.6. Diabetic Kidney Disease Historic and Forecast Sales By Regions
  • 8.7. Other Historic and Forecast Sales By Regions

9. GLOBAL LISINOPRIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 9.4. Retail Pharmacy Historic and Forecast Sales By Regions
  • 9.5. Online Pharmacy Historic and Forecast Sales By Regions

10. GLOBAL LISINOPRIL MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE LISINOPRIL COMPANIES

  • 11.1. Lisinopril Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF LISINOPRIL INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. AbbVie Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Amneal Pharmaceutical Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. AstraZeneca
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. Apotex Inc.
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Aurobindo Pharma Ltd.
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Bausch Health Companies Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Cipla Limited
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Hikma Pharmaceutical PLC.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Lupin Limited
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Merck & Co. Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. Pfizer Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Sun Pharmaceutical Industries Limited
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments
  • 12.15. Teva Pharmaceutical Industries Limited
    • 12.15.1 Company Overview
    • 12.15.2 Company Revenue
    • 12.15.3 Products
    • 12.15.4 Recent Developments
  • 12.16. Vitaris Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Company Revenue
    • 12.16.3 Products
    • 12.16.4 Recent Developments
  • 12.17. Zydus Lifesciences Limited
    • 12.17.1 Company Overview
    • 12.17.2 Company Revenue
    • 12.17.3 Products
    • 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies